SpringWorks Therapeutics (NASDAQ: SWTX)
$41.25
(1.9%)
$0.75
Price as of April 23, 2025, 3:58 p.m. ET
Key Data Points
Current Price
$41.25
Daily Change
(1.9%) $0.75
Day's Range
$40.38 - $42.09
Previous Close
$41.21
Open
$41.65
Beta
1.21
Volume
754
Average Volume
2,559,534
Sector
Market Cap
$3B
Market Cap / Employee
$8M
52wk Range
$28.21 - $62.00
Revenue
$192M
Gross Margin
91.64%
Dividend Yield
N/A
EPS
-$3.48
CAPs Rating
-
Industry
Biotechnology
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
SpringWorks Therapeutics Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
SpringWorks Therapeutics Company Info
Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, BGB-3245 (RAF Fusion and Dimer Inhibitor), SW-682 (TEAD Inhibitor), and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.
News & Analysis
Featured Article
What Company Will Eli Lilly Buy Next?
Following the announced buyout of Dermira, Eli Lilly’s management said more acquisitions are in store for 2020.
David Haen | Jan 23, 2020
Featured Article
Here's Why SpringWorks Therapeutics Climbed 69% in December
The stock climbed after investors saw encouraging signs from a similar program.
Cory Renauer | Jan 12, 2020
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.